Advance-HTN
65 evidence topics · 14 sources
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2023-03-13” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-01-15” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-01-15” (opens the source at this quote in a new tab)
“First Posted 2023-03-15” (opens the source at this quote in a new tab)
“Last Update Posted 2026-01-20” (opens the source at this quote in a new tab)
Number and country of locations in the ClinicalTrials.gov record
Number of sites stated in the trial presentation
Topline results announced in March 2025
Presentation at the American College of Cardiology Scientific Session in March 2025
Publication in April 2025
Study design
Official title and design in the ClinicalTrials.gov record
Design features stated in the trial presentation
“Multicenter (103 sites in the United States)” (opens the source at this quote in a new tab)
“Prospective” (opens the source at this quote in a new tab)
“Randomized” (opens the source at this quote in a new tab)
“Double-blind” (opens the source at this quote in a new tab)
“Placebo-controlled” (opens the source at this quote in a new tab)
“Parallel group” (opens the source at this quote in a new tab)
“Phase 2b trial” (opens the source at this quote in a new tab)
Trial periods and their durations in the trial presentation
| Period | Quoted record |
|---|---|
| Screening | “2 weeks” |
| Single-blind run-in on the standardized regimen | “3 weeks” |
| Randomized double-blind treatment | “12 weeks” |
| After the end of treatment | “Open-label extension”; “2-week end of study visit”; “4-week washout” |
Design stated in the publication abstract
“In this multicenter, double-blind, randomized, placebo-controlled trial, we assigned participants who were receiving two to five antihypertensive medications and had a blood-pressure measurement of 140/90 mm Hg or higher obtained during an office visit to undergo a standardized antihypertensive regimen for 3 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Role in the pivotal program stated by the company
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Age, sex, and healthy volunteers in the ClinicalTrials.gov record
Blood pressure, medication, and laboratory thresholds in the trial presentation
| Criterion | Quoted record |
|---|---|
| Background antihypertensive medications at screening | “2 - 5 BP medications” |
| Office blood pressure at screening | “SBP 140 to 180 mm Hg, or DBP 90 to 110 mm Hg” |
| 24-hour ambulatory blood pressure before randomization | “SBP 130 to 180 mm Hg, or DBP > 80 mm Hg” |
| Serum sodium | “Na+ ≥ 135” |
| Estimated glomerular filtration rate | “eGFR ≥ 45” |
Eligibility for randomization after the standardized regimen in the publication abstract
Treatment
Standardized antihypertensive regimen during the run-in
“Switch to standardized regimen:” (opens the source at this quote in a new tab)
“Indapamide 2.5 mg daily or HCTZ 25 mg daily” (opens the source at this quote in a new tab)
“Olmesartan 40 mg daily” (opens the source at this quote in a new tab)
“+/- Amlodipine 10 mg daily” (opens the source at this quote in a new tab)
Standardized regimen assigned by the number of prior medications
Randomized treatment arms in the ClinicalTrials.gov record
| Arm | Quoted record |
|---|---|
| Placebo comparator | “Placebo once daily for 12 weeks” |
| Experimental: Dose 1 | “lorundrostat Dose 1 once daily for 12 weeks” |
| Experimental: Dose 2 | “lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria” |
Doses and dose-adjustment rule in the publication abstract
“assigned to receive placebo, lorundrostat at a stable dose of 50 mg daily (the stable-dose group), or lorundrostat at a starting dose of 50 mg daily, with an increase to 100 mg daily if systolic blood pressure was 130 mm Hg or higher after 4 weeks (the dose-adjustment group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment duration and titration stated by the company
Study outcomes
Rationale for using change in 24-hour ambulatory systolic blood pressure as the primary endpoint
Registered primary outcome measure in the ClinicalTrials.gov record
Primary end point defined in the publication abstract
“The primary end point was the change in 24-hour average systolic blood pressure from baseline to week 12, assessed as the least-squares mean difference from placebo (the placebo-adjusted change) in each lorundrostat group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ambulatory blood pressure monitoring as the reference measurement, stated by the lead investigator
Ambulatory and clinic blood pressure as predictors of mortality
“Ambulatory blood pressure provides a more comprehensive assessment than clinic blood pressure, and has been reported to better predict health outcomes than clinic or home pressure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for clinic blood pressure, 24-h blood pressure remained strongly associated with all-cause deaths (HR 1·43 [95% CI 1·37-1·49]), but the association between clinic blood pressure and all-cause death was attenuated when adjusted for 24-h blood pressure (1·04 [1·00-1·09]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ambulatory blood pressure, particularly night-time blood pressure, was more informative about the risk of all-cause death and cardiovascular death than clinic blood pressure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-office blood pressure in the 2025 AHA/ACC guideline
Blood pressure reduction as the basis of cardiovascular benefit
Same primary endpoint in a phase 3 trial of another aldosterone synthase inhibitor
“The primary endpoint was change in 24 h ambulatory SBP from baseline to week 12, assessed by analysis of covariance in patients administered at least one dose of study medication with valid ambulatory SBP measurement at baseline and week 12.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary end points in the trial presentation
Key secondary end point defined in the publication abstract
Registered secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Participants randomized and analyzed for efficacy in the trial presentation
Participants in the primary and key secondary analyses stated by the company
Planned sample size and statistical power
No evidence found.
Description of analysis sets
Comparisons for the primary and key secondary end points in the publication abstract
“assessed as the least-squares mean difference from placebo (the placebo-adjusted change) in each lorundrostat group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“assessed as the placebo-adjusted change in the combined lorundrostat groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Control of multiplicity for the key secondary end points
Within-participant analysis for participants escalated to 100 mg
Hyperkalemia confirmed by repeat testing in the safety analysis
Results
Participant disposition
Screening, run-in, and randomization in the trial presentation
“2617 patients assessed for eligibility” (opens the source at this quote in a new tab)
“1691 ineligible” (opens the source at this quote in a new tab)
“926 enrolled & started standardized regimen” (opens the source at this quote in a new tab)
“641 ineligible” (opens the source at this quote in a new tab)
“53% due to ABPM” (opens the source at this quote in a new tab)
“285 randomized” (opens the source at this quote in a new tab)
“94 included in the efficacy analysis” (opens the source at this quote in a new tab)
Randomization by treatment group in the publication abstract
Baseline characteristics
Participant characteristics by treatment group in the trial presentation
| Characteristic | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
|---|---|---|---|
| Age (years) | “59” | “61” | “61” |
| Women (%) | “35%” | “40%” | “44%” |
| Black or African-American (%) | “46%” | “53%” | “58%” |
| BMI (kg/m2) | “32” | “31” | “32” |
| eGFR (randomization) | “74” | “77” | “76” |
| Office BP (screening) | “155/91” | “153/88” | “152/89” |
| 24-hour ABPM (randomization) | “141/87” | “141/86” | “141/87” |
Obesity, sex, and race stated by the company
Efficacy results
Primary end point: change in 24-hour average systolic blood pressure at week 12
“After 12 weeks, the least-squares mean change in 24-hour average systolic blood pressure was -15.4 mm Hg in the stable-dose group, -13.9 mm Hg in the dose-adjustment group, and -7.4 mm Hg in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The placebo-adjusted change in blood pressure was -7.9 mm Hg (97.5% confidence interval [CI], -13.3 to -2.6) in the stable-dose group and -6.5 mm Hg (97.5% CI, -11.8 to -1.2) in the dose-adjustment group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary end point: placebo-adjusted changes with P values in the trial presentation
Key secondary end point: change in 24-hour average systolic blood pressure at week 4, combined lorundrostat groups
“The placebo-adjusted change in 24-hour average systolic blood pressure from baseline to week 4 in the combined lorundrostat groups was -5.3 mm Hg (95% CI, -8.4 to -2.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Group | Least-squares mean change at week 4 (mm Hg) |
|---|---|
| Placebo | “-6.2” |
| Lorundrostat 50 mg (all) | “-11.5” |
| Placebo-adjusted difference | “Placebo-adjusted: -5.3 (-8.4 to -2.3) P < 0.001” |
Key secondary end point: 24-hour average systolic blood pressure below 125 mm Hg at week 4
| Group | Proportion with 24-hour average SBP <125 mm Hg at week 4 |
|---|---|
| Placebo | “18%” |
| Lorundrostat 50 mg (all) | “41%” |
| Odds ratio (95% CI) | “3.3 (1.4 to 7.8) P < 0.001” |
Key secondary end point: change at week 4 by number of background medications
| Background medications | Placebo n | Placebo change (mm Hg) | Lorundrostat n | Lorundrostat change (mm Hg) | Placebo-adjusted difference |
|---|---|---|---|---|---|
| 2 | “n = 60” | “-5.1” | “n = 117” | “-11.2” | “-6.1 (-10.8 to -1.4) P = 0.001” |
| 3 | “n = 34” | “-7.2” | “n = 71” | “-11.8” | “-4.6 (-10.6 to 1.5) P = 0.060” |
Key secondary end point: office systolic blood pressure at week 12 in participants escalated to 100 mg
Key secondary end point: relationship of body mass index to blood pressure reduction at week 4
Dose escalation compared with the stable 50 mg dose
Conclusion of the publication abstract
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events by treatment group in the trial presentation
| Adverse event | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
|---|---|---|---|
| Any serious AE | “2%” | “6%” | “8%” |
| Any study-drug related serious AE | “0” | “2%” | “1%” |
| Hypotension | “3%” | “9%” | “8%” |
| Hyponatremia | “6%” | “9%” | “11%” |
| Hyperkalemia (>6.0 mmol/L), single value | “0” | “5%” | “7%” |
| Hyperkalemia (>6.0 mmol/L), confirmed via per protocol repeat testing | “0” | “2%” | “3%” |
Hyperkalemia above 6.0 mmol per liter
“A potassium level above 6.0 mmol per liter occurred in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and no participants in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia in Advance-HTN compared with Launch-HTN
Serum electrolytes and cortisol stated by the company
Study limitations
Summary
Advance-HTN was a 12-week phase 2 trial (the presentation calls it a “Phase 2b trial”) in 285 randomized participants at sites in the United States only (104 locations in the registry record; 103 sites in the presentation). Every participant was switched to a standardized regimen of a diuretic, olmesartan, and, for those previously on 3 to 5 drugs, amlodipine, so the results describe lorundrostat added to that regimen and may differ from its effect on top of usual background therapy; the presenters list the need for “additional data using office blood pressure on top of usual care” from Launch-HTN as a limitation. Of 926 participants who started the standardized regimen, 641 were ineligible for randomization (53% because of the ambulatory blood pressure criterion), which selects a population with confirmed uncontrolled hypertension on a standardized regimen.
The 50 to 100 mg dose-adjustment strategy produced a smaller placebo-adjusted reduction at week 12 (-6.5 mm Hg) than the stable 50 mg dose (-7.9 mm Hg), and 19 participants were escalated to 100 mg, so the trial gives limited information on the 100 mg dose. The week 4 subgroup on 3 background medications (71 lorundrostat and 34 placebo participants) had a placebo-adjusted difference of -4.6 mm Hg with a confidence interval that crossed zero (P = 0.060). The placebo group had a 24-hour systolic reduction of 7.4 mm Hg at week 12.
Single-value potassium above 6.0 mmol/L occurred in 5.3% and 7.4% of the two lorundrostat groups (2.1% and 3.2% after confirmation by repeat testing). The trial was “Not head-to-head with other classes of antihypertensive medications” and “Not a cardiovascular or kidney outcome trial”. As of November 2026 no posted results were located in the registry record, and participant disposition after randomization, discontinuations for adverse events, mean changes in potassium, sodium, and eGFR, and daytime, nighttime, and office blood pressure results by arm are not reported in the publication abstract, the presentation, the registry record, or the company releases.